Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients With Hurler-Scheie or Scheie Syndrome Who Have Completed 8-Weeks of Dosing With AGT-181 in Study AGT-181-102

NCT02597114 is registered in ClinicalTrials.gov with ArmaGen, Inc as lead sponsor.

NCT NCT02597114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02597114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients With Hurler-Scheie or Scheie Syndrome Who Have Completed 8-Weeks of Dosing With AGT-181 in Study AGT-181-102
Lead sponsor
ArmaGen, Inc
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2015
Completion date
August 2, 2018
Enrollment
3 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis i